Business Description
AC Immune SA
NAICS : 325412
SIC : 2834
ISIN : CH0329023102
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 54.23 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.75 | |||||
Beneish M-Score | -3.45 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.8 | |||||
3-Year EBITDA Growth Rate | 8.9 | |||||
3-Year EPS without NRI Growth Rate | 6.7 | |||||
3-Year FCF Growth Rate | 4.4 | |||||
3-Year Book Growth Rate | -17.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 97.98 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.33 | |||||
9-Day RSI | 68.84 | |||||
14-Day RSI | 60.78 | |||||
6-1 Month Momentum % | 5.85 | |||||
12-1 Month Momentum % | 11.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.8 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 1.74 | |||||
Days Sales Outstanding | 349.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.3 | |||||
Shareholder Yield % | -0.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -376.44 | |||||
Net Margin % | -379.58 | |||||
FCF Margin % | 275.14 | |||||
ROE % | -43.45 | |||||
ROA % | -34.01 | |||||
ROIC % | -77.77 | |||||
3-Year ROIIC % | 10.08 | |||||
ROC (Joel Greenblatt) % | -742.93 | |||||
ROCE % | -40.89 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 9.39 | |||||
PS Ratio | 17.95 | |||||
PB Ratio | 2.66 | |||||
Price-to-Tangible-Book | 4.51 | |||||
Price-to-Free-Cash-Flow | 8.5 | |||||
Price-to-Operating-Cash-Flow | 8.33 | |||||
EV-to-EBIT | -2.38 | |||||
EV-to-Forward-EBIT | 4.1 | |||||
EV-to-EBITDA | -2.47 | |||||
EV-to-Revenue | 9.02 | |||||
EV-to-Forward-Revenue | 1.07 | |||||
EV-to-FCF | 3.33 | |||||
Price-to-Net-Current-Asset-Value | 4.92 | |||||
Price-to-Net-Cash | 5.41 | |||||
Earnings Yield (Greenblatt) % | -42.02 | |||||
FCF Yield % | 13.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
AC Immune SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 16.408 | ||
EPS (TTM) (€) | -0.665 | ||
Beta | 0.88 | ||
Volatility % | 115.2 | ||
14-Day RSI | 60.78 | ||
14-Day ATR (€) | 0.142384 | ||
20-Day SMA (€) | 2.86075 | ||
12-1 Month Momentum % | 11.25 | ||
52-Week Range (€) | 2.06 - 4.73 | ||
Shares Outstanding (Mil) | 98.94 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
AC Immune SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
AC Immune SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
AC Immune SA Frequently Asked Questions
What is AC Immune SA(FRA:IMR)'s stock price today?
When is next earnings date of AC Immune SA(FRA:IMR)?
Does AC Immune SA(FRA:IMR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |